| 摘要 |
The invention provides an in vitro method for predicting whether a patient would be responsive to a treatment with an anti-HER2 blocking agent, such as trastuzumab, which method comprises determining the expression level of at least 4 genes in a biological sample of said patient, wherein said genes are GPR22, PEX19, GRHL2 and DERL1. The invention further provides a DNA chip for performing such method. |
